Cargando…

Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia

BACKGROUND AND HYPOTHESIS: Optimal doses of most antipsychotics in the maintenance treatment of schizophrenia are unknown. We aimed to study the risk of severe relapse indicated by rehospitalization for different dose categories of 15 most frequently used antipsychotics in monotherapy in Finland. ST...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taipale, Heidi, Tanskanen, Antti, Luykx, Jurjen J, Solmi, Marco, Leucht, Stefan, Correll, Christoph U, Tiihonen, Jari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Regular Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212108/ https://www.ncbi.nlm.nih.gov/pubmed/35524479 http://dx.doi.org/10.1093/schbul/sbac039

Ejemplares similares

Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia—A Nationwide Study With 20-Year Follow-up
por: Taipale, Heidi, et al.
Publicado: (2018)

In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine
por: Luykx, Jurjen J., et al.
Publicado: (2020)

Primary Nonadherence to Antipsychotic Treatment Among Persons with Schizophrenia
por: Lieslehto, Johannes, et al.
Publicado: (2022)

Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
por: Tiihonen, Jari, et al.
Publicado: (2019)

Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia
por: Taipale, Heidi, et al.
Publicado: (2020)

Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse
por: Sommer, Iris E, et al.
Publicado: (2022)

Morbidity and mortality in schizophrenia with comorbid substance use disorders
por: Lähteenvuo, Markku, et al.
Publicado: (2021)

S210. COMPARATIVE EFFECTIVENESS OF ANTIPSYCHOTICS FOR RISK OF ATTEMPTED OR COMPLETED SUICIDE AMONG PERSONS WITH SCHIZOPHRENIA
por: Taipale, Heidi, et al.
Publicado: (2020)

Medication Use and Health Care Utilization After a Cost-sharing Increase in Schizophrenia: A Nationwide Analysis
por: Hamina, Aleksi, et al.
Publicado: (2020)

Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real‐World Study Across Antipsychotics
por: Stam, Noraly, et al.
Publicado: (2020)

Employment among people with schizophrenia or bipolar disorder: A population‐based study using nationwide registers
por: Holm, Minna, et al.
Publicado: (2020)

Effectiveness of antipsychotics in schizophrenia with comorbid substance use disorder
por: Lähteenvuo, M., et al.
Publicado: (2021)

Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia
por: Lintunen, Jonne, et al.
Publicado: (2021)

Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder
por: Lintunen, Jonne, et al.
Publicado: (2021)

Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring
por: Taipale, Heidi, et al.
Publicado: (2020)

The clinical course of schizophrenia in women and men—a nation-wide cohort study
por: Sommer, Iris E., et al.
Publicado: (2020)

Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
por: Puranen, Arto, et al.
Publicado: (2023)

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics
por: Kishimoto, Taishiro, et al.
Publicado: (2011)

Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland: a nationwide register-based study
por: Taipale, Heidi, et al.
Publicado: (2014)

Incidence and Duration of Cumulative Bisphosphonate Use among Community-Dwelling Persons with or without Alzheimer’s Disease
por: Tiihonen, Miia, et al.
Publicado: (2016)

Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials
por: Taipale, Heidi, et al.
Publicado: (2022)

Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 Patients
por: Heikkinen, Milja, et al.
Publicado: (2022)

Systemic Estrogen Use and Discontinuation After Alzheimer’s Disease Diagnosis in Finland 2005–2012: A Nationwide Exposure-Matched Cohort Study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2018)

Month and Season of Birth as a Risk Factor for Alzheimer’s Disease: A Nationwide Nested Case-control Study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2016)

Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer’s disease – exposure-matched cohort study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2016)

T208. EFFECTIVENESS OF PHARMACOLOGICAL THERAPIES FOR DELUSIONAL DISORDER
por: Lähteenvuo, Markku, et al.
Publicado: (2020)

Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer’s disease: a nationwide matched cohort study
por: Taipale, Heidi, et al.
Publicado: (2017)

Morbidity and mortality in schizophrenia with comorbid substance use disorders in Finland and Sweden
por: Lähteenvuo, M., et al.
Publicado: (2021)

Healthcare utilization, costs, and productivity losses in treatment-resistant depression in Finland – a matched cohort study
por: Taipale, Heidi, et al.
Publicado: (2022)

Twenty‐year medication use trends in first‐episode bipolar disorder
por: Poranen, Juulia, et al.
Publicado: (2022)

Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
por: Lähteenvuo, Markku, et al.
Publicado: (2021)

Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons
por: Taipale, Heidi, et al.
Publicado: (2016)

Real‐world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation‐wide cohort of 125 556 patients
por: Heikkinen, Milja, et al.
Publicado: (2021)

Real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort
por: Heikkinen, Milja, et al.
Publicado: (2022)

Comparative Effectiveness of Pharmacotherapies for the Risk of Attempted or Completed Suicide Among Persons With Borderline Personality Disorder
por: Lieslehto, Johannes, et al.
Publicado: (2023)

Effects of Substance Use and Antisocial Personality on Neuroimaging-Based Machine Learning Prediction of Schizophrenia
por: Taipale, Matias, et al.
Publicado: (2023)

Opioid Use After Hospital Care due to Hip Fracture Among Community-Dwelling Persons With and Without Alzheimer’s Disease
por: Lintula, Eveliina, et al.
Publicado: (2019)

Cause-specific excess mortality after first diagnosis of bipolar disorder: population-based cohort study
por: Paljärvi, Tapio, et al.
Publicado: (2023)

Antipsychotic Polypharmacy in Clozapine Resistant Schizophrenia: A Randomized Controlled Trial of Tapering Antipsychotic Co-treatment
por: Repo-Tiihonen, Eila, et al.
Publicado: (2012)

Correction to: Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s82a5165ior7g9ji1eaklqq541